Skip to content

CVCT CardioBrief

  • Home
  • About
    • Mission
  • CVCT Forum
  • Cardiobrief Archive
  • FAQ
    • Contact
    • Privacy Policy
    • Cookies Policy
    • Terms of use
  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
search
  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
search

Login / Signup

May 26, 20212021-05-26T06:58:17-04:00

Speculations on PARADISE-MI (sacubitril/valsartan post-MI) before the full results

By : Alexandra Nowbar

Marc Pfeffer presented the results of PARADISE-MI at ACC last week. As discussed previously on CVCTCardiobrief, sacubitril/valsartan did not reduce the primary outcome compared to…

January 23, 20172017-01-23T17:09:41-05:00

Long Unsuccessful Heart Failure Drug Once Again At Center Of Controversy

By : Larry Husten

–The long, strange 30-year journey of BiDil. It’s been buried in the avalanche of related news but there’s an interesting and somewhat bizarre cardiology angle…

April 01, 20142015-09-15T19:48:30-04:00

A New Novartis Heart Failure Drug Might Be A Blockbuster

By : Larry Husten

I try to avoid using words like “blockbuster” and “breakthrough” when writing about new drugs and treatments. I’ve been disappointed too many times. But, though…

July 25, 2013

Possible Cognitive Benefits Found In Dementia Patients Taking Centrally Acting ACE Inhibitors

By : Larry Husten

An observational study from Ireland raises the intriguing possibility that certain blood pressure lowering drugs, centrally acting ACE inhibitors, may help slow the cognitive decline that is…

July 03, 2012

Many CHF Patients Not Receiving– Or Getting Benefits From– High Dose ACE Inhibitors And ARBs

By : Larry Husten

Although current guidelines recommend that ACE inhibitors and angiotensin-receptor blockers (ARBs) be used in high doses in patients with congestive heart failure, many CHF patients…

  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use